Kalif Eliyahu Sharon 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 2, 2026
Research Summary
AI-generated summary of this filing
Teva (TEVA) CFO Kalif Eliyahu Sharon Sells 345,810 Shares
What Happened
Kalif Eliyahu Sharon, Chief Financial Officer of Teva Pharmaceutical Industries Ltd (TEVA), sold 345,810 shares on February 26, 2026 in open-market/private sale transactions. The weighted-average sale price was $33.64, producing total proceeds of approximately $11,634,708. The reported sales were completed under a pre-established Rule 10b5-1 trading plan.
Key Details
- Transaction date: February 26, 2026; Form 4 filed March 2, 2026.
- Transaction type: Sale (S) — open market or private sale.
- Shares sold: 345,810; weighted-average price: $33.64. Individual sale prices ranged from $33.57 to $33.86.
- Proceeds: ~$11,634,708.
- Shares owned after the transaction: Not disclosed in the provided excerpt (see the full Form 4 for post-transaction holdings).
- Notable footnotes:
- F2: Sale executed pursuant to a Rule 10b5-1 trading plan adopted Nov 26, 2025.
- F3: Reported price is a weighted average; seller will provide breakdown of fills/prices upon request.
- F1: Teva’s ordinary shares may be represented by American Depositary Shares (each currently represents one ordinary share).
Context
Insider sales are often routine (for diversification, liquidity, or tax reasons); a 10b5-1 plan indicates trades were pre-planned and can reduce concerns about trading on nonpublic information but does not reveal motivation. Purchases generally provide stronger signals of insider confidence than sales. For full details (post-transaction holdings, precise timing, and per-trade prices), consult the complete Form 4 (Accession: 0001193125-26-085343).
Insider Transaction Report
- Sale
Ordinary Shares
[F1][F2][F3]2026-02-26$33.64/sh−345,810$11,634,708→ 57,478 total
Footnotes (3)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.57 to $33.86, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.